Silexion Therapeutics Corp Ordinary Shares Share Price
NASDAQ: SLXN | Micro CapSilexion Therapeutics Corp Ordinary Shares Stock Performance
Open $1.83 | Prev. Close $1.79 | Circuit Range N/A |
Day Range $1.83 - $1.94 | Year Range $0.23 - $8.49 | Volume 541 |
Average Traded $1.90 |
Silexion Therapeutics Corp Ordinary Shares Share Price Today
As of 10 August 2026, Silexion Therapeutics Corp Ordinary Shares's share price is $1.89. The stock opened at $1.83, compared to its previous close of $1.79. During today's trading session, Silexion Therapeutics Corp Ordinary Shares's share price traded between $1.83 and $1.94, with an average price of $1.89. Over the past 52 weeks, the stock has recorded a high of $8.49 and a low of $0.23. In terms of performance, Silexion Therapeutics Corp Ordinary Shares's share price has risen by 9.57% over the last six months and is down 75.10% on a year-on-year basis.
Silexion Therapeutics Corp Ordinary Shares Share Price Chart
Silexion Therapeutics Corp Ordinary Shares Stock Fundamentals & Key Indicators
Market Cap $2.51M | PE Ratio (TTM) 0.21 | Dividend Yield N/A |
EPS (TTM) $8.96 | Revenue (TTM) N/A | Return On Equity (TTM) -457.63% |
Profit Margin N/A | Debt to Equity 1.06 | Quarterly Earnings Growth YoY 72.50% |
Silexion Therapeutics Corp Ordinary Shares Quarterly Profit & Loss
All figures in USD
Silexion Therapeutics Corp Ordinary Shares Annual Profit & Loss
All figures in USD
About Silexion Therapeutics Corp Ordinary Shares
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Silexion Therapeutics Corp Ordinary Shares Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $1.84 | $1.90 | +2.15% |
Jul 2026 | $2.66 | $1.86 | -25.90% |
Jun 2026 | $4.89 | $2.51 | -49.50% |
May 2026 | $0.59 | $4.97 | +702.91% |
Apr 2026 | $1.25 | $0.62 | -49.67% |
Mar 2026 | $1.68 | $1.23 | -28.70% |
Feb 2026 | $1.70 | $1.73 | -6.25% |
Jan 2026 | $2.18 | $1.84 | -7.07% |
Dec 2025 | $2.75 | $1.98 | -31.96% |
Nov 2025 | $3.25 | $2.91 | -11.82% |
Oct 2025 | $3.36 | $3.30 | -2.37% |
Sep 2025 | $6.95 | $3.38 | -55.47% |
SLXN Share Price FAQs
What is Silexion Therapeutics Corp Ordinary Shares share price today?
What is the 52 week high and 52 week low of Silexion Therapeutics Corp Ordinary Shares stock?
What is SLXN's market capitalisation today?
What is SLXN's net income for the last quarter?
What is the 5 year returns of SLXN?
What is the high & low stock price of SLXN today?
Can I buy SLXN shares in India?